These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 21994136)

  • 1. Ultra-rapid virological response, young age, low γ-GT/ALT-ratio, and absence of steatosis identify a subgroup of HCV Genotype 3 patients who achieve SVR with IFN-α(2a) monotherapy.
    Amanzada A; Goralczyk A; Moriconi F; Blaschke M; Schaefer IM; van Thiel D; Mihm S; Ramadori G
    Dig Dis Sci; 2011 Nov; 56(11):3296-304. PubMed ID: 21994136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
    Aziz H; Raza A; Ali K; Khattak JZ; Irfan J; Gill ML
    Int J Infect Dis; 2015 Jan; 30():91-7. PubMed ID: 25462177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High predictability of a sustained virological response (87%) in chronic hepatitis C virus genotype 1 infection treatment by combined IL28B genotype analysis and γ-glutamyltransferase/alanine aminotransferase ratio: a retrospective single-center study.
    Amanzada A; Goralczyk AD; Schneider S; Moriconi F; Lindhorst A; Mihm S; Van Thiel DH; Ramadori G
    Digestion; 2012; 86(3):218-27. PubMed ID: 22964578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
    Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
    Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
    Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
    Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.
    Tohra SK; Taneja S; Ghosh S; Sharma BK; Duseja A; Dhiman RK; Das A; Chawla YK
    Dig Dis Sci; 2011 Aug; 56(8):2449-55. PubMed ID: 21706207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
    Aziz H; Raza A; Waheed Y; Gill U; Gill ML
    Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b.
    Pellicelli AM; Romano M; Stroffolini T; Mazzoni E; Mecenate F; Monarca R; Picardi A; Bonaventura ME; Mastropietro C; Vignally P; Andreoli A; Marignani M; D'Ambrosio C; Miglioresi L; Nosotti L; Mitidieri O; Gentilucci UV; Puoti C; Barbaro G; Barlattani A; Furlan C; Barbarini G;
    BMC Gastroenterol; 2012 Nov; 12():162. PubMed ID: 23157720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
    Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR
    Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C.
    Christensen PB; Krarup HB; Laursen AL; Madsen PH; Pedersen C; Schlichting P; Orholm M; Ring-Larsen H; Bukh J; Krogsgaard K
    Scand J Gastroenterol; 2012 Sep; 47(8-9):1115-9. PubMed ID: 22670704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C.
    Aizawa N; Enomoto H; Takashima T; Sakai Y; Iwata K; Ikeda N; Tanaka H; Iwata Y; Saito M; Imanishi H; Iijima H; Nishiguchi S
    J Gastroenterol; 2014 Aug; 49(8):1253-63. PubMed ID: 24065124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.
    Mach TH; Cieśla A; Warunek W; Janas-Skulina U; Cibor D; Owczarek D; Ciećko-Michalska I
    Pol Arch Med Wewn; 2011 Dec; 121(12):434-9. PubMed ID: 22157768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1.
    Amanzada A; Schneider S; Moriconi F; Lindhorst A; Suermann T; van Thiel DH; Mihm S; Ramadori G
    J Med Virol; 2012 Aug; 84(8):1208-16. PubMed ID: 22711348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C?
    Veillon P; Fouchard-Hubert I; Larrey D; Dao MT; D'alteroche L; Boyer-Darrigand N; Picard N; Le Guillou-Guillemette H; Saulnier P; Ducancelle A; Loustaud-Ratti V; Lunel-Fabiani F
    J Interferon Cytokine Res; 2016 Mar; 36(3):204-14. PubMed ID: 26700738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.